These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

230 related items for PubMed ID: 2549986

  • 1. Competitive inhibition of tritium-labeled platelet-activating factor binding to rabbit platelet membranes by amiloride and amiloride analogs.
    Hwang SB.
    Biochem Biophys Res Commun; 1989 Aug 30; 163(1):165-71. PubMed ID: 2549986
    [Abstract] [Full Text] [Related]

  • 2. Specific binding of [3H]dihydrokadsurenone to rabbit platelet membranes and its inhibition by the receptor agonists and antagonists of platelet-activating factor.
    Hwang SB, Lam MH, Chang MN.
    J Biol Chem; 1986 Oct 15; 261(29):13720-6. PubMed ID: 3020044
    [Abstract] [Full Text] [Related]

  • 3. MK 287: a potent, specific, and orally active receptor antagonist of platelet-activating factor.
    Hwang SB, Lam MH, Szalkowski DM, MacIntyre DE, Bach TJ, Luell S, Meuer R, Sahoo SP, Alberts AW, Chabala JC.
    J Lipid Mediat; 1993 Jun 15; 7(2):115-34. PubMed ID: 8400114
    [Abstract] [Full Text] [Related]

  • 4. Characterization of platelet-activating factor (PAF) receptor by specific binding of [3H]L-659,989, a PAF receptor antagonist, to rabbit platelet membranes: possible multiple conformational states of a single type of PAF receptors.
    Hwang SB, Lam MH, Hsu AH.
    Mol Pharmacol; 1989 Jan 15; 35(1):48-58. PubMed ID: 2536468
    [Abstract] [Full Text] [Related]

  • 5. L-659,989: a useful probe in the detection of multiple conformational states of PAF receptors.
    Hwang SB, Lam MH.
    Lipids; 1991 Dec 15; 26(12):1148-53. PubMed ID: 1668109
    [Abstract] [Full Text] [Related]

  • 6. Biochemical and pharmacological characterization of L-659,989: an extremely potent, selective and competitive receptor antagonist of platelet-activating factor.
    Hwang SB, Lam MH, Alberts AW, Bugianesi RL, Chabala JC, Ponpipom MM.
    J Pharmacol Exp Ther; 1988 Aug 15; 246(2):534-41. PubMed ID: 2841449
    [Abstract] [Full Text] [Related]

  • 7. High affinity specific binding sites for tritiated platelet-activating factor in canine platelet membranes: counterparts of platelet-activating factor receptors mediating platelet aggregation.
    Tahraoui L, Floch A, Mondot S, Cavero I.
    Mol Pharmacol; 1988 Aug 15; 34(2):145-51. PubMed ID: 2842653
    [Abstract] [Full Text] [Related]

  • 8. 1,4-Dihydropyridines, a new class of platelet-activating factor receptor antagonists: in vitro pharmacologic studies.
    Ortega MP, García MC, Gijón MA, de Casa-Juana MF, Priego JG, Sanchez Crespo M, Sunkel C.
    J Pharmacol Exp Ther; 1990 Oct 15; 255(1):28-33. PubMed ID: 2170624
    [Abstract] [Full Text] [Related]

  • 9. Ex vivo effects of SR 27417, a novel PAF antagonist, on rabbit platelet aggregation and [3H]-PAF binding.
    Herbert JM, Laplace MC, Maffrand JP.
    J Lipid Mediat; 1992 Feb 15; 5(1):1-12. PubMed ID: 1327264
    [Abstract] [Full Text] [Related]

  • 10. Inhibition by CV-3988 of the binding of [3H]-platelet activating factor (PAF) to the platelet.
    Terashita Z, Imura Y, Nishikawa K.
    Biochem Pharmacol; 1985 May 01; 34(9):1491-5. PubMed ID: 2986648
    [Abstract] [Full Text] [Related]

  • 11. Pharmacologic characterization of the rabbit neutrophil receptor for platelet-activating factor.
    Paulson SK, Wolf JL, Novotney-Barry A, Cox CP.
    Proc Soc Exp Biol Med; 1990 Nov 01; 195(2):247-54. PubMed ID: 2172997
    [Abstract] [Full Text] [Related]

  • 12. Continuous binding of the PAF molecule to its receptor is necessary for the long-term aggregation of platelets.
    Suzuki M, Sugatani J, Ino M, Shimura M, Akiyama M, Yamazaki R, Suzuki Y, Miwa M.
    Am J Physiol; 1998 Jan 01; 274(1):C47-57. PubMed ID: 9458712
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Functional validation of platelet-activating factor receptor sites characterized biochemically by a specific and reproducible [3H]platelet-activating factor binding in human platelets.
    Tahraoui L, Floch A, Cavero I.
    J Pharmacol Exp Ther; 1990 Mar 01; 252(3):1221-7. PubMed ID: 2156995
    [Abstract] [Full Text] [Related]

  • 18. A specific, photolabile and irreversible antagonist (L662,025) of the PAF-receptor.
    Hussaini IM, Shen TY.
    Biochem Biophys Res Commun; 1989 May 30; 161(1):23-30. PubMed ID: 2543410
    [Abstract] [Full Text] [Related]

  • 19. PAF binding sites. Characterization by [3H]52770 RP, a pyrrolo[1,2-c]thiazole derivative, in rabbit platelets.
    Robaut C, Durand G, James C, Lave D, Sedivy P, Floch A, Mondot S, Pacot D, Cavero I, Le Fur G.
    Biochem Pharmacol; 1987 Oct 01; 36(19):3221-9. PubMed ID: 2822048
    [Abstract] [Full Text] [Related]

  • 20. Radioligand competitive binding methodology for the evaluation of platelet-activating factor (PAF) and PAF-receptor antagonism using intact canine platelets.
    Janero DR, Burghardt B, Burghardt C.
    J Pharmacol Methods; 1988 Nov 01; 20(3):237-53. PubMed ID: 2853256
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.